Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

摘要

Rituximab (R) (Rituxan?, Roche, Basel Switzerland) is the first anti- CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma and B-cell chronic lympho- cytic leukemia [1]. Administered intravenously (IV), it has been shown to be also efficient to treat other hematologic situations such as EBV reactivation, especially after hematopoietic stem cell transplantation (HSCT), [2] or ITP [3]. Finally, survivals of younger patients with CD20-positive Philadelphia-negative ALL are significantly increased when combining IV-R with chemotherapy [4].